112 related articles for article (PubMed ID: 7909118)
1. Parvovirus B19 and blood products.
Guillaume T
Lancet; 1994 Apr; 343(8905):1101. PubMed ID: 7909118
[No Abstract] [Full Text] [Related]
2. Parvovirus B19 and blood products.
Prowse CV
Lancet; 1994 Apr; 343(8905):1101. PubMed ID: 7909119
[No Abstract] [Full Text] [Related]
3. Eliminating parvovirus B19 from blood products.
Santagostino E; Mannucci PM; Gringeri A; Azzi A; Morfini M
Lancet; 1994 Mar; 343(8900):798. PubMed ID: 7907759
[No Abstract] [Full Text] [Related]
4. [Transmission of parvovirus B19 by blood and blood components].
Schwarz TF
Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():27-31. PubMed ID: 8000251
[TBL] [Abstract][Full Text] [Related]
5. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates.
Lefrère JJ; Mariotti M; Thauvin M
Lancet; 1994 Jan; 343(8891):211-2. PubMed ID: 7904670
[TBL] [Abstract][Full Text] [Related]
6. Heat sensitivity of human parvovirus B19.
Yunoki M; Tsujikawa M; Urayama T; Sasaki Y; Morita M; Tanaka H; Hattori S; Takechi K; Ikuta K
Vox Sang; 2003 Apr; 84(3):164-9. PubMed ID: 12670364
[TBL] [Abstract][Full Text] [Related]
7. Parvovirus B19 antibodies in patients with haemophilia A.
Peerlinck K; Goubau P; Reybrouck R; Desmyter J; Vermylen J
Thromb Haemost; 1995 Mar; 73(3):555-6. PubMed ID: 7667846
[No Abstract] [Full Text] [Related]
8. Life-threatening human parvovirus B19 infection in immunocompetent haemophilia.
Yee TT; Lee CA; Pasi KJ
Lancet; 1995 Mar; 345(8952):794-5. PubMed ID: 7605434
[No Abstract] [Full Text] [Related]
9. Transmission of human parvovirus B19 by plasma derived factor VIII concentrates.
Laurian Y; Dussaix E; Parquet A; Chalvon-Demersay A; d'Oiron R; Tchernia G
Nouv Rev Fr Hematol (1978); 1994 Dec; 36(6):449-53. PubMed ID: 7753615
[TBL] [Abstract][Full Text] [Related]
10. Human Parvovirus B19 and blood product safety: a tale of twenty years of improvements.
Marano G; Vaglio S; Pupella S; Facco G; Calizzani G; Candura F; Liumbruno GM; Grazzini G
Blood Transfus; 2015 Apr; 13(2):184-96. PubMed ID: 25849894
[No Abstract] [Full Text] [Related]
11. [Severe parvovirus B19 infection in an immunocompetent child with hemophilia A].
Coumau E; Peynet J; Harzic M; Béal G; Castaigne S; Leverger G; Foucaud P
Arch Pediatr; 1996 Jan; 3(1):35-9. PubMed ID: 8745824
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of human parvovirus B19 DNA contamination of factor VIII products.
Matsunaga Y
Dev Biol Stand; 1996; 88():217. PubMed ID: 9119140
[No Abstract] [Full Text] [Related]
13. B19 parvovirus and blood transfusion.
Morinet F
Dev Biol Stand; 1993; 81():45-7. PubMed ID: 8174819
[TBL] [Abstract][Full Text] [Related]
14. Should measures be taken to reduce the risk of human parvovirus (B19) infection by transfusion of blood components and clotting factor concentrates?
Mosley JW
Transfusion; 1994 Sep; 34(9):744-6. PubMed ID: 8091460
[No Abstract] [Full Text] [Related]
15. [Virus in hemophilia: current status and future perspectives].
Aguilar C; Félix Lucía J
Sangre (Barc); 1996 Apr; 41(2):141-5. PubMed ID: 9045355
[No Abstract] [Full Text] [Related]
16. Human parvovirus B19. Virus transmissible in blood products.
Snowden JA; Ali-Wali WI
BMJ; 1994 Feb; 308(6928):595. PubMed ID: 8148692
[No Abstract] [Full Text] [Related]
17. Frequent human parvovirus B19 DNA occurrence and high seroprevalence in haemophilic patients from a non-metropolitan blood centre, Brazil.
Slavov SN; Kashima S; Rocha-Junior MC; Oliveira LC; Silva-Pinto AC; Yamamoto AY; Covas DT
Transfus Med; 2014 Apr; 24(2):130-2. PubMed ID: 24684574
[No Abstract] [Full Text] [Related]
18. Parvovirus B19: an expanding spectrum of disease.
Cohen B
BMJ; 1995 Dec; 311(7019):1549-52. PubMed ID: 8520401
[No Abstract] [Full Text] [Related]
19. Evaluation of a new LightCycler reverse transcription-polymerase chain reaction infectivity assay for detection of human parvovirus B19 in dry-heat inactivation studies.
Prikhod'ko GG; Vasilyeva I; Reyes H; Wong S; Brown KE; Jameson T; Busby TF
Transfusion; 2005 Jun; 45(6):1011-9. PubMed ID: 15935001
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools.
Rollag H; Patou G; Pattison JR; Degré M; Evensen SA; Fröland SS; Glomstein A
Scand J Infect Dis; 1991; 23(6):675-9. PubMed ID: 1815327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
